- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.04. | HAMLET BIOPHARMA AB: Monthly investor meeting on the 29th of April | 1 | Cision News | ||
| 30.03. | HAMLET BIOPHARMA AB: Hamlet BioPharma presented at the Financial Stockholm event on March 26, 2026 | 1 | Cision News | ||
| HAMLET BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 17.03. | HAMLET BIOPHARMA AB: Hamlet BioPharmas digital monthly investor meeting on the 18th of March | 1 | Cision News | ||
| 06.03. | HAMLET BIOPHARMA AB: Hamlet BioPharma signed a Letter of Intent to outline terms of a potential collaboration and a commercial agreement concerning Alpha 1H. | 3 | Cision News | ||
| 13.02. | HAMLET BIOPHARMA AB: Q2 INTERIM REPORT OCT - DEC 2025 | 1 | Cision News | ||
| 12.02. | HAMLET BIOPHARMA AB: Nature Microbiology publishes the paper "Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial." | 1 | Cision News | ||
| 11.02. | HAMLET BIOPHARMA AB: Monthly investor meeting on the 13th of February when Hamlet BioPharma is releasing it's Q2 report | 2 | Cision News | ||
| 03.02. | HAMLET BIOPHARMA AB: Collaboration agreement between Hamlet BioPharma and Immunoforge in South Korea | 1 | Cision News | ||
| 16.01. | HAMLET BIOPHARMA AB: Invitation to digital meeting focusing on novel strategies for treating bacterial infections without antibiotics | 1 | Cision News | ||
| 18.12.25 | HAMLET BIOPHARMA AB: The HAMLET project featured in Cancerfonden's Christmas Campaign | 1 | Cision News | ||
| 14.11.25 | HAMLET BIOPHARMA AB: Q1 INTERIM REPORT JULY - SEPT 2025 | 1 | Cision News | ||
| 10.11.25 | HAMLET BIOPHARMA AB: Hamlet BioPharma Receives FDA Pivotal-Study Feedback for Novel Neoadjuvant Therapy in Non-Muscle Invasive Bladder Cancer | 1 | Cision News | ||
| 05.11.25 | HAMLET BIOPHARMA AB: Clinical study in infants with febrile kidney infection supports Hamlet BioPharma's strategy for non-antibiotic treatment of bacterial infections | 1 | Cision News | ||
| 24.09.25 | Hamlet BioPharma AB: Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation | 577 | PR Newswire | At 12 months, mean eGFR was 51.5 mL/min/1.73m2 in the imlifidase arm versus 19.3 mL/min/1.73m2 in the control arm with a statistically significant and clinically meaningful difference of... ► Artikel lesen | |
| 21.08.25 | Hamlet BioPharma AB (publ): Hamlet BioPharma Announces the Completion of the Alpha1H Phase II Study in Non-Muscle Invasive Bladder Cancer | 218 | PR Newswire | LUND, Sweden, Aug. 21, 2025 /PRNewswire/ -- Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections... ► Artikel lesen | |
| 04.07.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 04.07.2025 | 956 | Xetra Newsboard | The following instruments on XETRA do have their first trading 04.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 04.07.2025
Aktien
1 SGXE14976547 Meituan SDR
2 SGXE81412038... ► Artikel lesen | |
| 25.06.25 | Hamlet BioPharma AB (publ): Hamlet BioPharma Holds Successful In Person Meeting with US FDA | 447 | PR Newswire | LUND, Sweden, June 25, 2025 /PRNewswire/ -- Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ETON PHARMACEUTICALS | 28,910 | +19,86 % | Eton Pharmaceuticals relaunches HEMANGEOL (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution | HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiationEton has integrated full Eton Cares patient support, including $0 co-pay for eligible... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 86,91 | -1,18 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| LB PHARMACEUTICALS | 31,355 | -1,12 % | This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | ||
| BIOHAVEN | 9,630 | +0,57 % | Biohaven Ltd.: Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results | Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM)... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,390 | -1,83 % | KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer | ||
| AQUESTIVE THERAPEUTICS | 4,190 | +2,07 % | Vergessene Biotech-Chance: Kann Aquestive Therapeutics vor dem Durchbruch stehen? | Aquestive Therapeutics steht trotz operativer Fortschritte und potenziell wertvoller Pipeline unter massivem Bewertungsdruck. Die Aktie notiert deutlich unter früheren Kursniveaus, während sich fundamentale... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,340 | +4,46 % | Weekly Buzz: Sanofi, Regeneron Pharmaceuticals Get FDA Nod; It's A No For AbbVie, Grace Therapeutics; Eli Lilly Acquires Kelonia | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning... ► Artikel lesen | |
| SHUTTLE PHARMACEUTICALS | 0,708 | -31,93 % | Shuttle Pharmaceuticals Holdings Inc.: United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation | Gaithersburg, Maryland--(Newsfile Corp. - May 1, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin... ► Artikel lesen | |
| OMNIAB | 1,400 | +0,72 % | OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026 | ||
| MILESTONE PHARMACEUTICALS | 1,870 | +3,89 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST (etripamil) Nasal Spray for the Treatment of PSVT | FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic... ► Artikel lesen | |
| JOURNEY MEDICAL | 5,185 | +0,68 % | Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately... ► Artikel lesen | |
| DARE BIOSCIENCE | 2,350 | +3,07 % | Daré Bioscience, Inc.: Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update | Company Highlights Commercial Launch of DARE to PLAY Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 13,110 | +3,80 % | Generate Biomedicines Prices IPO At $16/shr | WASHINGTON (dpa-AFX) - Generate Biomedicines, Inc. (GENB) on Thursday priced its initial public offering of 25,000,000 shares of stock at $16 per share, raising gross proceeds of $400 million.The... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 1,905 | +0,79 % | Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity | WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 13,400 | +4,93 % | Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration | SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics... ► Artikel lesen |
Das Unternehmen HAMLET BIOPHARMA AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,41 % bei einem Aktienkurs von 0,727 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HAMLET BIOPHARMA AB finden Sie auf Wallstreet Online.